Plain-English translation of NCT07490041 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which uses specially engineered immune cells to help children whose rheumatic diseases (like juvenile arthritis or lupus) have not improved with standard medications. The cells are designed to target specific cells in the immune system that drive these diseases. Researchers want to see if this medication is safe and whether it can help children who have run out of other treatment options.
Children with severe rheumatic diseases sometimes do not respond to current treatments, leaving them with ongoing pain, joint damage, and complications. This trial exists to explore whether a new cell-based approach could help these children when traditional therapies have failed.
You likely qualify if…
You likely don't qualify if…
You will receive two chemotherapy medications (fludarabine and cyclophosphamide) over three days to prepare your body, followed by multiple doses of the engineered cell therapy . The trial involves visits to the hospital or clinic for infusions, blood tests, and monitoring for side effects. The full duration of participation and follow-up care will be explained by the research team, as this is an early-stage study designed to evaluate safety and how well the treatment works.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China